MA35064B1 - Dérivés de thiéno[2,3-d]pyrimidine et leur utilisation pour traiter l'arythmie - Google Patents

Dérivés de thiéno[2,3-d]pyrimidine et leur utilisation pour traiter l'arythmie

Info

Publication number
MA35064B1
MA35064B1 MA36364A MA36364A MA35064B1 MA 35064 B1 MA35064 B1 MA 35064B1 MA 36364 A MA36364 A MA 36364A MA 36364 A MA36364 A MA 36364A MA 35064 B1 MA35064 B1 MA 35064B1
Authority
MA
Morocco
Prior art keywords
thieno
pyrimidine derivatives
treating arrhythmia
arrhythmia
relates
Prior art date
Application number
MA36364A
Other languages
English (en)
Inventor
Derek Edward John
John Ford
Original Assignee
Xention Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44071904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35064(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Xention Ltd filed Critical Xention Ltd
Publication of MA35064B1 publication Critical patent/MA35064B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés thiénopyrimidine qui sont des inhibiteurs de canaux potassiques. Elle concerne également des compositions pharmaceutiques comprenant les composés et leur utilisation dans le traitement de l'arythmie.
MA36364A 2011-04-01 2012-03-29 Dérivés de thiéno[2,3-d]pyrimidine et leur utilisation pour traiter l'arythmie MA35064B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1105659.5A GB201105659D0 (en) 2011-04-01 2011-04-01 Compounds
PCT/GB2012/050710 WO2012131379A1 (fr) 2011-04-01 2012-03-29 Dérivés de thiéno[2,3-d]pyrimidine et leur utilisation pour traiter l'arythmie

Publications (1)

Publication Number Publication Date
MA35064B1 true MA35064B1 (fr) 2014-04-03

Family

ID=44071904

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36364A MA35064B1 (fr) 2011-04-01 2012-03-29 Dérivés de thiéno[2,3-d]pyrimidine et leur utilisation pour traiter l'arythmie

Country Status (42)

Country Link
US (1) US9249155B2 (fr)
EP (1) EP2694518B1 (fr)
JP (1) JP5826374B2 (fr)
KR (1) KR20140023332A (fr)
CN (1) CN103492392B (fr)
AP (1) AP2013007198A0 (fr)
AR (1) AR088735A1 (fr)
AU (1) AU2012235882B2 (fr)
BR (1) BR112013025236A2 (fr)
CA (1) CA2831493A1 (fr)
CL (1) CL2013002789A1 (fr)
CO (1) CO6801756A2 (fr)
CR (1) CR20130488A (fr)
CU (1) CU24173B1 (fr)
CY (1) CY1117025T1 (fr)
DK (1) DK2694518T3 (fr)
EA (1) EA201301111A1 (fr)
EC (1) ECSP13012988A (fr)
ES (1) ES2558563T3 (fr)
GB (1) GB201105659D0 (fr)
GT (1) GT201300225A (fr)
HK (2) HK1193096A1 (fr)
HR (1) HRP20151340T1 (fr)
HU (1) HUE028438T2 (fr)
IL (1) IL228555A0 (fr)
MA (1) MA35064B1 (fr)
ME (1) ME02314B (fr)
MX (1) MX335937B (fr)
NI (1) NI201300100A (fr)
PE (1) PE20141021A1 (fr)
PL (1) PL2694518T3 (fr)
PT (1) PT2694518E (fr)
RS (1) RS54458B1 (fr)
RU (1) RU2013148627A (fr)
SG (1) SG193578A1 (fr)
SI (1) SI2694518T1 (fr)
SM (1) SMT201500322B (fr)
TN (1) TN2013000377A1 (fr)
TW (1) TWI516265B (fr)
UA (1) UA110131C2 (fr)
WO (1) WO2012131379A1 (fr)
ZA (1) ZA201307085B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150307532A1 (en) * 2012-11-20 2015-10-29 The Royal Institution For The Advancement Of Learning/Mcgill University Thienopyrimidine inhibitors of farnesyl and/or geranylgeranyl pyrophosphate synthase
JP7114076B2 (ja) 2015-12-22 2022-08-08 シャイ・セラピューティクス・エルエルシー がん及び炎症性疾患の処置のための化合物
CN106727587A (zh) * 2016-11-28 2017-05-31 李娜 一种治疗心律失常的药物组合物
MX2019014875A (es) 2017-06-21 2021-01-29 SHY Therapeutics LLC Compuestos que interaccionan con la superfamilia ras para el tratamiento de cancer, enfermedades inflamatorias, rasopatias y enfermedad fibrotica.

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH317906A (de) 1953-09-16 1956-12-15 Sandoz Ag Verfahren zur Herstellung von 1-Amino-4-oxyanthrachinonsulfonsäuren
AU521790B2 (en) 1977-05-23 1982-04-29 Ici Australia Limited Process for eradication of ticks
US4196207A (en) 1977-05-23 1980-04-01 Ici Australia Limited Process for controlling eradicating or preventing infestations of animals by Ixodid ticks
DD226893A1 (de) 1981-12-15 1985-09-04 Ralf Boehm Verfahren zur herstellung von arylaminosubstituierten thieno 2,3-d pyrimidinen
IL112569A (en) 1994-02-10 1999-12-22 Wyeth John & Brother Ltd Pharmaceutical compositions comprising cyclohexylamine derivatives certain such novel compounds and their preparation
IL112568A0 (en) 1994-02-10 1995-05-26 Wyeth John & Brother Ltd Substituted quinolines, their preparation and pharmaceutical compositions containing them
IL112566A (en) 1994-02-10 2000-10-31 Wyeth John & Brother Ltd Substituted quinolinones and pharmaceutical compositions containing them
IL112567A (en) 1994-02-10 2000-02-29 Wyeth John & Brother Ltd Substituted quinolines their preparation and pharmaceutical compositions containing them
CA2227384A1 (fr) 1995-08-17 1997-02-27 Toshifumi Watanabe Derives de thienopyrimidine, leur fabrication et leurs applications
AU713573B2 (en) 1996-07-26 1999-12-02 Nissan Chemical Industries Ltd. Chroman derivatives
US6083986A (en) 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
US5969017A (en) 1996-10-31 1999-10-19 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
US5935945A (en) 1996-10-31 1999-08-10 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
RU2116309C1 (ru) 1997-02-13 1998-07-27 Институт медицинской паразитологии и тропической медицины им.Е.И.Марциновского 4-[(бензо-2,1,3-тиадиазолил-4)амино]-5,6,7,8-тетрагидробензотиено [2,3-d]пиримидин, обладающий противогельминтной активностью при ларвальном альвеолярном эхинококкозе
US6333337B1 (en) 1998-01-27 2001-12-25 Icagen, Inc. Potassium channel inhibitors
CA2334258A1 (fr) 1998-06-05 1999-12-09 Icagen, Inc. Inhibiteurs des canaux de potassium
AU5444499A (en) 1998-09-01 2000-03-21 Nissan Chemical Industries Ltd. Benzoxazine derivatives
US6194458B1 (en) 1998-10-30 2001-02-27 Merck & Co., Inc. Benzamide potassium channel inhibitors
DE19929076A1 (de) 1999-06-25 2000-12-28 Aventis Pharma Gmbh Indanylsubstituierte Benzolcarbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
SK3292002A3 (en) 1999-09-17 2003-04-01 Nissan Chemical Ind Ltd Benzopyran derivative
US6555574B1 (en) 1999-09-24 2003-04-29 Nissan Chemical Industries, Ltd. 4-oxybenzopyran derivative
US6531495B1 (en) 1999-10-02 2003-03-11 Aventis Pharma Deutschland Gmbh 2′-Substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them
DE19947457A1 (de) 1999-10-02 2001-04-05 Aventis Pharma Gmbh 2'-Substituierte 1,1'-Biphenyl-2-carbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen
AU7453900A (en) 1999-10-05 2001-05-10 Nissan Chemical Industries Ltd. 4-oxybenzopyran derivative
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
AU781365B2 (en) 1999-12-21 2005-05-19 Icagen, Inc. Potassium channel inhibitors
JP4854909B2 (ja) 2000-09-20 2012-01-18 メルク・シャープ・エンド・ドーム・コーポレイション イソキノリノン系カリウムチャンネル阻害剤
DE10054481A1 (de) 2000-11-03 2002-05-08 Aventis Pharma Gmbh Acylaminoalkyl-substituierte Benzolsulfonamidderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE10059418A1 (de) 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10060807A1 (de) 2000-12-07 2002-06-20 Aventis Pharma Gmbh Ortho, ortho-substituierte stickstoffhaltige Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10061876A1 (de) 2000-12-12 2002-06-20 Aventis Pharma Gmbh Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10104802A1 (de) 2001-02-02 2002-08-08 Merck Patent Gmbh Pharmazeutische Formulierungen enthaltend Thienopirimidine und Endothelin-Rezeptor-Antagonisten (1)
CA2437085A1 (fr) 2001-02-02 2002-08-15 Merck Patent Gesellschaft Mit Beschraenkter Haftung Preparation pharmaceutique comprenant des pyrazolo[4,3-d]pyrimidines et des antagonistes du recepteur de l'endotheline ou des thienopyrimidines et des antagonsites du recepteur del'endotheline
TW589305B (en) 2001-02-14 2004-06-01 Nissan Chemical Ind Ltd 4-aminobenzopyran derivatives
DE10121003A1 (de) 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10121002A1 (de) 2001-04-28 2002-11-14 Aventis Pharma Gmbh Verwendung von Anthranilsäureamiden als Medikament zur Behandlung von Arrhythmien sowie sie enthaltende pharmazeutische Zubereitungen
DE10128331A1 (de) 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
CN1279036C (zh) 2001-06-25 2006-10-11 日产化学工业株式会社 抗心律失常的取代的苯并吡喃衍生物
TW200307539A (en) 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
ES2324536T7 (es) 2003-06-11 2012-03-16 Xention Limited Derivados de tenopirimidina como inhibidores de los canales de potasio.
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
CN1845918A (zh) * 2003-07-02 2006-10-11 沃泰克斯药物股份有限公司 可用作电压－门控离子通道调节剂的嘧啶
US7557111B2 (en) 2004-01-06 2009-07-07 Taisho Pharmaceutical Co., Ltd. Substituted thieno[3,2-d]pyrimidines as CRF receptor antagonists
WO2006004658A2 (fr) 2004-06-29 2006-01-12 Amgen Inc. Furanopyrimidines
JP5173429B2 (ja) 2004-12-09 2013-04-03 ゼンション・リミテッド 化合物
US7576212B2 (en) 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
WO2007084815A2 (fr) 2006-01-19 2007-07-26 Janssen Pharmaceutica, N.V. Inhibiteurs de la thienopyrimidine kinase substituee
EP2043654A2 (fr) * 2006-06-12 2009-04-08 Vertex Pharmaceuticals, Inc. Thiénopyrimidines utiles en tant que modulateurs de canaux ioniques
DE102009039893B4 (de) 2009-09-03 2012-03-29 Bundesanstalt für Materialforschung und -Prüfung (BAM) Verwendung eines Brennstoffs in einem selbstunterhaltenden pulsierenden Sauerstoff-Brennstoff-Verbrennungsprozess

Also Published As

Publication number Publication date
KR20140023332A (ko) 2014-02-26
HK1193096A1 (zh) 2014-09-12
UA110131C2 (ru) 2015-11-25
CU24173B1 (es) 2016-04-25
CR20130488A (es) 2013-12-06
ZA201307085B (en) 2015-04-29
SMT201500322B (it) 2016-02-25
WO2012131379A1 (fr) 2012-10-04
HK1193806A1 (zh) 2014-10-03
AR088735A1 (es) 2014-07-02
CN103492392A (zh) 2014-01-01
EP2694518A1 (fr) 2014-02-12
ME02314B (me) 2016-06-20
BR112013025236A2 (pt) 2019-09-24
US9249155B2 (en) 2016-02-02
CL2013002789A1 (es) 2014-07-18
IL228555A0 (en) 2013-12-31
RS54458B1 (en) 2016-06-30
US20140206703A1 (en) 2014-07-24
AU2012235882B2 (en) 2015-08-06
ES2558563T3 (es) 2016-02-05
NZ615621A (en) 2015-01-30
EP2694518B1 (fr) 2015-10-07
SI2694518T1 (sl) 2016-02-29
GB201105659D0 (en) 2011-05-18
RU2013148627A (ru) 2015-05-10
TN2013000377A1 (en) 2015-01-20
CO6801756A2 (es) 2013-11-29
NI201300100A (es) 2014-01-07
CN103492392B (zh) 2015-11-25
TW201244720A (en) 2012-11-16
GT201300225A (es) 2014-12-30
CU20130124A7 (es) 2014-01-29
EA201301111A1 (ru) 2014-02-28
CA2831493A1 (fr) 2012-10-04
ECSP13012988A (es) 2013-12-31
MX2013011301A (es) 2014-04-16
CY1117025T1 (el) 2017-04-05
AU2012235882A1 (en) 2013-05-02
TWI516265B (zh) 2016-01-11
DK2694518T3 (en) 2015-11-09
PE20141021A1 (es) 2014-08-30
MX335937B (es) 2016-01-04
PT2694518E (pt) 2016-02-05
SG193578A1 (en) 2013-10-30
HRP20151340T1 (hr) 2016-02-26
AP2013007198A0 (en) 2013-10-31
JP5826374B2 (ja) 2015-12-02
PL2694518T3 (pl) 2016-03-31
JP2014509637A (ja) 2014-04-21
HUE028438T2 (en) 2017-02-28

Similar Documents

Publication Publication Date Title
MA39092A1 (fr) Pyrrolo[2,3-d]pyrimidinyle, pyrrolo[2,3-b]pyrazinyle et pyrollo[2,3-d]pyridinyle acrylamides
EA201500393A1 (ru) Ингибиторы тирозинкиназы брутона
MA38347A1 (fr) Dérivés de pyrrolo[2,3-d]pyrimidine en tant qu'inhibiteurs de janus kinases (jak)
PH12015501067A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
MA41251B1 (fr) Dérivés de thiéno[2,3-c]pyrrol-4-one comme inhibiteurs erk
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
TN2012000146A1 (fr) Derives de pyrrolo[2,3-d]pyrimidine
EA200901157A1 (ru) Конденсированные кольцевые гетероциклические модуляторы киназы
EA202090662A3 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ И ДРУГИХ ЗАБОЛЕВАНИЙ
UA111588C2 (uk) Композиція інгібітора jak для місцевого застосування
MA47356B1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
EA201291098A1 (ru) Новые соединения 3,5-дизамещенного-3h-имидазо[4,5-b]пиридина и 3,5-дизамещенного -3h-[1,2,3]триазоло[4,5-b]пиридина как модуляторы протеинкиназ
EA201400161A1 (ru) Замещенные гетероароматические пиразолсодержащие карбоксамидные и мочевинные производные в качестве лигандов ваниллоидных рецепторов
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
MA35816B1 (fr) Dérivés d'aniline, leur préparation et leur application thérapeutique
UA114001C2 (xx) Оксазолідин-2-он-піримідинові похідні
MX2013002118A (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MA35064B1 (fr) Dérivés de thiéno[2,3-d]pyrimidine et leur utilisation pour traiter l'arythmie
MA38678A1 (fr) Dérivés nucléosidiques 4'-azido, 3'désoxy-3'-fluoro substitués
UA111520C2 (uk) [1,2,4]триазолопіридини і їх застосування як інгібіторів фосфодіестерази
EA201491522A1 (ru) Способы лечения нарушения походки и/или равновесия у пациентов с рассеянным склерозом с использованием аминопиридина
MX2013002295A (es) 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
GEP201706657B (en) Quinoline derivatives as pde10a enzyme inhibitors